Sleep News and Research

Latest Sleep News and Research

Depomed announces SPA agreement with FDA for Serada Phase 3 trial for menopausal hot flashes

Depomed, Inc. announced today that it has reached agreement with the U.S. Food and Drug Administration regarding a Special Protocol Assessment on the design and analysis of Breeze 3, a Phase 3 trial evaluating Serada® (extended release gabapentin tablets) for menopausal hot flashes.

11 Aug 2010

Jazz Pharmaceuticals second-quarter net product sales increase 49% to $39.5 million

Jazz Pharmaceuticals, Inc. announced financial results for the second quarter ended June 30, 2010 and updated financial guidance for 2010. The company's updated financial guidance reflects higher expected sales of XYREM® (sodium oxybate) and the effects of recent financing activities.

11 Aug 2010

Infants of emotionally receptive parents have reduced sleep disruptions: Study

Parents understand the challenge of getting infants to sleep through the night, and now Penn State researchers show that being emotionally receptive can reduce sleep disruptions and help infants and toddlers sleep better.

11 Aug 2010

Labopharm launches antidepressant OLEPTRO for major depressive disorder in U.S.

Labopharm Inc. today announced that OLEPTRO(TM) (trazodone hydrochloride extended-release tablets), a novel once-daily formulation of the antidepressant trazodone, has been launched in the United States by its joint venture with Gruppo Angelini, Angelini Labopharm. OLEPTRO(TM) is indicated for the treatment of major depressive disorder (MDD) in adults. The efficacy of OLEPTRO(TM) has been established in a trial of outpatients with MDD as well as in trials with the immediate release formulation of trazodone.

11 Aug 2010

Graymark Healthcare second-quarter consolidated net revenues increase 12% to $28.3 million

Graymark Healthcare, Inc. today announced financial results for the quarter ending June 30, 2010 including $1.1MM of EBITDA on $28.3MM in sales.

10 Aug 2010

Transcept Pharmaceuticals second-quarter net loss decreases to $2.06 million

Transcept Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced financial results for the three and six months ended June 30, 2010.

10 Aug 2010

Texas Children's Hospital provides tips to ensure healthy and successful school year

It's August and for many families that means it's time to head back to school. From sleep schedules, nutrition, immunizations, heart health, heat illnesses and more, Texas Children's Hospital in Houston provides parents with tips to ensure their children have a safe, healthy and successful school year.

10 Aug 2010

Brain-wave pattern study may lead to techniques for enhancing sleep spindles

People who have trouble sleeping in noisy environments often resort to strategies like earplugs or noise-cancelling headphones that muffle the sound, but a new study from investigators at Massachusetts General Hospital (MGH) may lead to ways to block disturbing sounds within the brain. In their report in the August 10 issue of Current Biology, the team reports finding a brain-wave pattern, reflecting activity of a key structure, that predicts the ease at which sleep can be disrupted by noise.

10 Aug 2010

Mild sleep restriction for several nights can affect cognitive tasks: Research

Many people are sleep restricted, either because they have to or because they choose to be, she says. "Instead of going to bed when they are tired, like they should, people watch TV and want to have an active social life," she says. "People count on catching up on their sleep on the weekends, but it may not be enough."

10 Aug 2010

Endo to acquire Penwest for $5.00 per share

Endo Pharmaceuticals today announced actions designed to advance the company's leadership and growth in pain management, including an agreement to acquire all outstanding shares of Penwest Pharmaceuticals for $5.00 in cash per share, or an estimated enterprise value of approximately $144 million at the time of deal close. Penwest has been working with Endo since 1997 on the development and commercialization of OPANA® ER and receives a royalty stream on net sales of the product.

10 Aug 2010

Sound sleepers show distinct pattern of spontaneous brain rhythms: Research

Ever wonder why some people can sleep through just about anything, while others get startled awake at each and every bump in the night? A new report in the August 10th issue of Current Biology, a Cell Press publication, offers some insight: sound sleepers show a distinct pattern of spontaneous brain rhythms.We found that by measuring brain waves during sleep, we could learn a lot about how well a person's brain can block the negative effects of sounds; the more sleep spindles your brain produces, the more likely you'll stay asleep, even when confronted with noise, said Jeffrey Ellenbogen of Harvard Medical School.

10 Aug 2010

Scientists work towards creating a vaccine for Parkinson's disease

Nina Brown, 68, and millions of others with a debilitating neurological condition called Parkinson's disease are counting on researchers for a cure. At The University of Texas Health Science Center at Houston (UTHealth), protein chemists are working to develop a therapeutic vaccine.

10 Aug 2010

ResMed revenue increases 16% to $291.6 million for quarter ended June 30, 2010

ResMed Inc. today announced record revenue and income for the quarter ended June 30, 2010, and a two-for-one stock split.

From ResMed Corp 6 Aug 2010

Vanda second-quarter 2010 revenues decrease by $4.1M

Vanda Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced financial and operational results for the second quarter and six months ended June 30, 2010.

5 Aug 2010

Rotech Healthcare second-quarter adjusted EBITDA increases to $29.2 million

Rotech Healthcare Inc. today announced financial results for the three and six months ended June 30, 2010.

5 Aug 2010

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® and REBETOL® significantly increased the number of patients who achieved sustained virologic response, compared to control groups that received Peg/riba plus placebo.

5 Aug 2010

Healing Touch helps to restore normal energy balance

Greenwich Hospital surgical, labor and delivery, and oncology patients are among those who have received a healing boost through a form of energy therapy known as Healing Touch.The hospital, known for its reputation of service excellence, is among a growing number of medical facilities utilizing Healing Touch, which is a gentle, noninvasive therapy shown to facilitate the relaxation response to enhance the healing process. Research shows that, in addition to inducing a deep sense of calm and relaxation, Healing Touch helps to reduce pain, decrease anxiety, promote sleep and improve an overall sense of well-being.

5 Aug 2010

Mothers of premature babies have high levels of stress and anxiety

The incidence of premature babies has been stable or even increased over time. The phenomenon brings with it the possibility of neurological, sensorial, respiratory, cognitive or psychomotor consequences for the child, both in the short and the medium term. These consequences also are a concern to child psychiatrists and psychologists, as it is currently known that the progress of a premature baby and the appearance or otherwise of problems depend largely on the family environment, above all how the mother interacts with her child in the first months of its life.

5 Aug 2010

VIVUS second-quarter total revenue decreases to $3.9 million

VIVUS, Inc., a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today reported its financial results for the second quarter and six months ended June 30, 2010.

3 Aug 2010

Tips for caregivers to better manage their loved one's health care

According to the National Alliance for Caregiving, more than 65 million people in the United States serve as informal caregivers, typically for family members. This equates to more than one out of every four people serving as unpaid caregivers.

2 Aug 2010